SMC1B: A Potential Drug Target and Biomarker (G27127)

Target Name: SMC1B

NCBI ID: G27127

SMC1B

SMC1B: A Potential Drug Target and Biomarker

Spermidine SMC1B (SMC-1B) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of microRNA (miRNA) expression in various organisms, including humans. SMC1B has has been shown to play a critical role in the regulation of cell proliferation, apoptosis, and tissue homeostasis. Its function as a drug target makes it an attractive target for small molecule inhibitors, leading to a growing interest in the development of SMC1B inhibitors for therapeutic purposes.

SMC1B is a member of the Spermidine family, members of which play important roles in many biological processes. By interacting with other molecules, SMC1B plays a key role in the regulation of cell cycle, apoptosis, and tissue homeostasis. These functions make SMC1B an attractive drug target.

In recent years, researchers have discovered multiple functions of SMC1B, such as participating in cell cycle control, regulating apoptosis, regulating extracellular vesicle formation, etc. These functions make SMC1B a potential drug target. In addition, SMC1B can also serve as a potential biomarker for predicting disease progression and treatment response.

During the drug discovery process, researchers often use high-throughput screening methods, such as RNA interference (RNAi) technology, to screen and identify inhibitors of SMC1B. These inhibitors can inhibit the function of SMC1B, thereby causing it to lose its regulatory effect on the cell cycle, apoptosis regulation, etc. Through these methods, researchers have discovered multiple SMC1B inhibitors with potential therapeutic effects and are further optimizing and developing these drugs to improve their clinical effects.

In addition to being a drug target, SMC1B can also serve as a potential biomarker. In cancer research, SMC1B expression levels often change, becoming an important indicator of tumor progression and treatment response. By detecting the expression level of SMC1B, researchers can evaluate tumor progression and treatment effects, thereby providing more accurate guidance for tumor treatment.

Overall, SMC1B is a drug target with great potential and can also be used as a potential biomarker for disease diagnosis and treatment. As technology continues to develop, researchers will continue to explore the role of SMC1B in biological processes.

Protein Name: Structural Maintenance Of Chromosomes 1B

Functions: Meiosis-specific component of cohesin complex. Required for the maintenance of meiotic cohesion, but not, or only to a minor extent, for its establishment. Contributes to axial element (AE) formation and the organization of chromatin loops along the AE. Plays a key role in synapsis, recombination and chromosome movements. The cohesin complex is required for the cohesion of sister chromatids after DNA replication. The cohesin complex apparently forms a large proteinaceous ring within which sister chromatids can be trapped. At anaphase, the complex is cleaved and dissociates from chromatin, allowing sister chromatids to segregate. The meiosis-specific cohesin complex probably replaces mitosis specific cohesin complex when it dissociates from chromatin during prophase I (By similarity)

The "SMC1B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SMC1B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets